Lyudmila Bazhenova, MD, discusses the FDA’s expanded approval of taletrectinib for ROS1-positive non–small cell lung cancer.
|Articles|September 24, 2014
- Gynecologic Cancers (Issue 1)
- Volume 1
- Issue 1
The Role of Molecular Testing in Gynecologic Cancers
Author(s)Maurie Markman, MD
Maurie Markman, MD, discusses the role of molecular testing in gynecologic cancers.
Advertisement
Maurie Markman, MD, senior vice president for Clinical Affairs and National Director for Medical Oncology, Cancer Treatment Centers of America, Eastern Regional Medical Center, discusses the role of molecular testing in gynecologic cancers.
View more about screening for ovarian cancer > >
Articles in this issue
about 12 years ago
Trabectedin as a Treatment Option for Patients with Ovarian Cancerabout 12 years ago
Dream Team Aims To Change the Face of Ovarian Cancer Researchabout 12 years ago
On The Horizon for Ovarian Cancer: Potentially Promising Treatmentsabout 12 years ago
Cediranib Versus Olaparib in Recurrent Platinum-Sensitive Ovarian CancerAdvertisement
Related to this article
Natera’s blood test analyzes cell-free DNA to screen for several cancer types from a single sample.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dostarlimab Receives FDA Approval for MSI-H/dMMR Locally Advanced Rectal Cancer
2
Dr Bazhenova on the Updated FDA Label for Taletrectinib in ROS1+ NSCLC
3
MC001 Receives FDA Fast Track Designation in Pancreatic Cancer
4
FDA Accepts NDA for UGN-103 in Recurrent LG-IR-NMIBC
5